GC Biopharma Crescita futura

Future criteri di controllo 3/6

GC Biopharma prevede che gli utili e i ricavi cresceranno rispettivamente di 104.4% e 8.8% all'anno. Si prevede che l'EPS crescerà di 109.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 4.7% in 3 anni.

Informazioni chiave

104.4%

Tasso di crescita degli utili

109.9%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	66.0%
Tasso di crescita dei ricavi	8.8%
Rendimento futuro del capitale proprio	4.7%
Copertura analitica	Good
Ultimo aggiornamento	05 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Nov 19

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Nov 07

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Mar 08

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

May 02

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

Mar 10

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Feb 18

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

Jan 31

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

Jan 14

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Dec 27

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 09

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 21

Previsioni di crescita degli utili e dei ricavi

KOSE:A006280 - Stime future degli analisti e dati finanziari passati (KRW Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	2,020,583	61,500	45,175	75,850	6
12/31/2025	1,871,067	42,467	35,550	81,267	6
12/31/2024	1,716,417	4,200	-75,925	8,800	6
6/30/2024	1,618,467	-38,195	-139,830	-52,998	N/A
3/31/2024	1,633,972	-29,491	-129,119	-32,186	N/A
12/31/2023	1,626,644	-26,632	-130,474	-5,473	N/A
9/30/2023	1,633,172	1,858	-126,608	-4,056	N/A
6/30/2023	1,653,489	25,441	-71,639	49,959	N/A
3/31/2023	1,643,852	36,611	-49,949	67,601	N/A
12/31/2022	1,711,313	65,453	24,464	119,154	N/A
9/30/2022	1,702,128	108,541	12,484	115,958	N/A
6/30/2022	1,708,169	124,737	16,869	120,190	N/A
3/31/2022	1,672,535	114,840	44,668	153,978	N/A
12/31/2021	1,537,826	123,212	2,515	125,979	N/A
9/30/2021	1,552,271	86,257	-24,132	81,764	N/A
6/30/2021	1,506,143	93,472	-25,449	76,551	N/A
3/31/2021	1,478,566	99,854	-47,063	50,242	N/A
12/31/2020	1,504,115	80,886	-65,247	35,974	N/A
9/30/2020	1,438,540	44,131	-90,027	19,423	N/A
6/30/2020	1,385,465	7,169	-114,883	18,617	N/A
3/31/2020	1,381,597	-8,068	-112,056	33,761	N/A
12/31/2019	1,357,117	1,341	-106,132	40,291	N/A
9/30/2019	1,352,625	21,663	-83,775	51,994	N/A
6/30/2019	1,338,420	14,322	-60,757	49,220	N/A
3/31/2019	1,324,106	23,943	-73,864	13,184	N/A
12/31/2018	1,334,878	34,429	-50,257	14,410	N/A
9/30/2018	1,314,527	32,485	-50,357	3,751	N/A
6/30/2018	1,318,285	42,928	-60,438	-10,559	N/A
3/31/2018	1,306,606	64,339	N/A	-2,504	N/A
12/31/2017	1,287,916	53,247	N/A	57,879	N/A
9/30/2017	1,282,593	76,100	N/A	62,699	N/A
6/30/2017	1,254,113	71,435	N/A	94,298	N/A
3/31/2017	1,227,485	62,300	N/A	90,021	N/A
12/31/2016	1,197,904	62,970	N/A	-1,742	N/A
9/30/2016	1,146,958	40,707	N/A	37,325	N/A
6/30/2016	1,114,394	75,617	N/A	-2,588	N/A
3/31/2016	1,079,274	87,817	N/A	19,702	N/A
12/31/2015	1,047,812	94,967	N/A	45,244	N/A
9/30/2015	1,035,748	96,613	N/A	14,718	N/A
6/30/2015	1,023,133	84,250	N/A	27,796	N/A
3/31/2015	990,420	68,220	N/A	44,867	N/A
12/31/2014	975,327	83,945	N/A	56,763	N/A
9/30/2014	959,764	86,914	N/A	40,360	N/A
6/30/2014	937,735	75,576	N/A	39,249	N/A
3/31/2014	908,456	79,108	N/A	4,286	N/A
12/31/2013	888,168	70,066	N/A	29,689	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che A006280 diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.7% ).

Guadagni vs Mercato: Si prevede che A006280 diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede A006280 diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di A006280 ( 8.8% all'anno) crescerà più lentamente rispetto al mercato KR ( 9.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di A006280 ( 8.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di A006280 sarà basso tra 3 anni ( 4.7 %).

GC Biopharma Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 10% to ₩195,000

Price target increased by 11% to ₩188,333

Price target increased by 7.7% to ₩162,000

Consensus EPS estimates fall from profit to ₩269 loss

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Recent updates

Benign Growth For GC Biopharma Corp. (KRX:006280) Underpins Stock's 25% Plummet

Does This Valuation Of GC Biopharma Corp. (KRX:006280) Imply Investors Are Overpaying?

Price target increased by 10% to ₩195,000

Now 21% overvalued after recent price rise

Is GC Biopharma (KRX:006280) A Risky Investment?

Price target increased by 11% to ₩188,333

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Price target increased by 7.7% to ₩162,000

There's No Escaping GC Biopharma Corp.'s (KRX:006280) Muted Revenues

Now 21% overvalued after recent price rise

A Look At The Fair Value Of GC Biopharma Corp. (KRX:006280)

New major risk - Financial position

Is GC Biopharma (KRX:006280) A Risky Investment?

Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma Corp.'s (KRX:006280) Business And Shares Still Trailing The Industry

Upcoming dividend of ₩1,750 per share at 1.4% yield

GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

Consensus EPS estimates fall from profit to ₩269 loss

GC Biopharma Applies for MFDS Approval

Consensus EPS estimates fall from profit to ₩1,046 loss

Consensus EPS estimates fall by 31%

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 18%, revenue downgraded

GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt

Consensus EPS estimates fall by 38%

Consensus EPS estimates increase by 11%

GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to ₩176,750

Upcoming dividend of ₩2,000 per share

Price target decreased to ₩191,222

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to ₩208,875

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased to ₩254,400

GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

Investor sentiment improved over the past week

Price target decreased to ₩310,167

Consensus forecasts updated

Upcoming dividend of ₩1,500 per share

Price target decreased to ₩418,333

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

Price target increased to ₩434,000

Price target increased to ₩383,000

First quarter 2021 earnings released: EPS ₩1,293 (vs ₩368 loss in 1Q 2020)

US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

We Think Green Cross (KRX:006280) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩7,087 (vs ₩118 in FY 2019)

Are Green Cross Corporation's (KRX:006280) Mixed Financials Driving The Negative Sentiment?

New 90-day low: ₩333,500

GC Pharma Finalises Agreement with Moderna and the Government of the Republic of Korea for Covid-19 Vaccines Distribution

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

Shareholders Are Thrilled That The Green Cross (KRX:006280) Share Price Increased 268%

Green Cross Corporation, Annual General Meeting, Mar 25, 2021

Green Cross (KRX:006280) Has A Somewhat Strained Balance Sheet

New 90-day high: ₩505,000

GC Pharma and Clinigen K.K. Announces Marketing Approval for Hunterase ICV Injection 15 mg

Calculating The Intrinsic Value Of Green Cross Corporation (KRX:006280)

New 90-day high: ₩475,000

What You Need To Know About Green Cross Corporation's (KRX:006280) Investor Composition

Upcoming Dividend of ₩1,000 Per Share

Green Cross Corporation's (KRX:006280) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Does Green Cross's (KRX:006280) Statutory Profit Adequately Reflect Its Underlying Profit?